Glenmark India
A new way for a new world
Respiratory : Our Commitment
to Respiratory Health
Disclaimer :
You are advised to seek specific medical advice from a qualified medical practitioner for any diagnosis and / or treatment depending upon your specific condition.
This page contains only general information about Glenmark Products and the same shall in no way be construed as a substitute for medical advice. Glenmark uses reasonable efforts to update the information provided, some information may become obsolete over a period of time. Glenmark makes no claims or warranties as to the accuracy, completeness or use of the information nor accepts any liability to update the above information.
At Glenmark, we are deeply committed to addressing the rising incidence of respiratory diseases, which impact the quality of life for millions globally. Our focus is not just on treating symptoms but on improving long-term respiratory health through innovative treatments. Whether managing simple conditions like a persistent cough or complex, chronic diseases such as Allergic Rhinitis, Asthma, and Chronic Obstructive Pulmonary Disease (COPD), we offer a broad range of solutions tailored to meet the needs of patients.
We have strengthened our position as a leading player in respiratory care by introducing specialized medications that address critical patient needs. Our portfolio now includes advanced therapies designed to ensure precise medication delivery, allowing patients to experience significant improvements in lung function. For example, our recent launches in Allergic Rhinitis, Asthma, and Chronic Obstructive Pulmonary Disease (COPD) management focus on reducing the frequency and severity of symptoms, helping patients regain control over their lives.
We are proud to have become the second largest player in the nebulization market this year, moving up two ranks. Nebulization plays a crucial role in respiratory care by delivering medication directly into the lungs, making it easier for patients, especially children and the elderly, to manage their conditions. Our commitment to innovation and patient care continues to drive our leadership in this critical therapeutic area.
At Glenmark, we are deeply committed to addressing the rising incidence of respiratory diseases, which impact the quality of life for millions globally. Our focus is not just on treating symptoms but on improving long-term respiratory health through innovative treatments. Whether managing simple conditions like a persistent cough or complex, chronic diseases such as Allergic Rhinitis, Asthma, and Chronic Obstructive Pulmonary Disease (COPD), we offer a broad range of solutions tailored to meet the needs of each patient.
We have strengthened our position as a leading player in respiratory care by introducing specialized medications that address critical patient needs. Our portfolio now includes advanced therapies designed to ensure precise medication delivery, allowing patients to experience significant improvements in lung function. For example, our recent launches in Allergic Rhinitis, Asthma, and Chronic Obstructive Pulmonary Disease (COPD) management focus on reducing the frequency and severity of symptoms, helping patients regain control over their lives.
We are proud to have become the second largest player in the nebulization market this year, moving up two ranks. Nebulization plays a crucial role in respiratory care by delivering medication directly into the lungs, making it easier for patients, especially children and the elderly, to manage their conditions. Our commitment to innovation and patient care continues to drive our leadership in this critical therapeutic area.